Mavacamten safety study for heart muscle disease in Japan
Treatments studied
Part of Heart & circulation clinical trials.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have obstructive hypertrophic cardiomyopathy
- You are starting treatment with Mavacamten for the approved reason
- You receive treatment at a medical institution in Japan during the enrollment period
- You are not taking Mavacamten for a different condition than approved
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study looks at whether adjusting the dose of mavacamten based on heart function helps people with obstructive hypertrophic cardiomyopathy feel better and have fewer side effects. It is for people who are already on mavacamten and want to see if a personalized dose approach works.
This study collects blood samples and medical information from people with obstructive hypertrophic cardiomyopathy to learn why the medication mavacamten works differently in different people. The goal is to understand how genes and other factors influence treatment response, which may help personalize care.
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
This study checks how safe the drug mavacamten is for Korean patients with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM). It is for people who are already prescribed the drug by their doctor.
Hear when a new Obstructive Hypertrophic Cardiomyopathy (oHCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.